-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Prostatitis is one of the most common diseases in urology, with a lifetime prevalence of about 9%.
Given the insidious and diverse symptoms of chronic prostatitis (CP), the diagnosis of CP is difficult, and there are concerns that patients with symptoms of CP but not diagnosed (CPS) do not receive sufficient medical attention
.
Japanese researchers conducted a survey on the prevalence of CP and CPS and the patient's health-related quality of life (QOL), and the relevant results were published in the journal Prostate Cancer Prostatic Dis.
Research background
CP can impair the patient's QOL, but the full impact of CP, including CPS, on patients is unclear
.
Therefore, this study aimed to evaluate the effects
of confirmed CP (DCP) and CPS on QOL.
Study design
The researchers surveyed a representative sample of males aged 20-84 years across Japan to determine the prevalence of DCP and CPS, where CPS was defined based on previous studies and the Chronic Prostatitis Symptom Index Score (NIH-CPSI) (perineal and/or ejaculatory pain/discomfort, and NIH-CPSI pain subscale score ≥4), and tested the robustness of
the Nickel criterion through two sensitivity analyses 。 The investigators assessed participants' QOL using the Brief Health Questionnaire (SF-12) and compared
the participants' scores with those of Japanese men with normal, benign prostatic hyperplasia (BPH).
Research results
Among 5010 participants, the prevalence of DCP was 1.
4% and CPS was 3.
7%, and the two sensitivity analyses showed CPS prevalence of 3.
1% and 4.
5%,
respectively.
Fig.
1 Prevalence of DCP and CPS under different definitions
The prevalence of DCP and CPS differed significantly in age: DCP was most common in people aged 80-84 years, while the age distribution of CPS was bimodal, peaking in the 30-39 and 80-84 age groups
.
CPS was more common in younger participants (CPS prevalence was 5.
7% and DCP was only 0.
9% in groups 30-39).
Fig.
2 Age distribution of DCP and CPS
QOL results showed that patients with DCP and CPS generally had poorer QOL: CP patients scored on average lower than the Japanese average in most areas of SF-12, while mental health areas also scored lower than BPH patients
.
CP patients scored lowest
in the 8 domains of SF-12 for emotional function.
Figure 3 SF-12 scores in each area
Conclusion of the study
CP is a common condition in men and there is still a problem of underdiagnosis, especially in young men.
Whether diagnosed or not, CP seriously affects the QOL of
patients.
Given its prevalence and harmfulness, there is an urgent need to develop a simple and effective evaluation tool to help urologists better identify and manage patients with
CP.
References:
Sugimoto M, Hijikata Y, Tohi Y, et al.
Low quality of life in men with chronic prostatitis-like symptoms.
Prostate Cancer Prostatic Dis.
2022 Jun 25.
Editor: Mumu Wang
Review: LR
Execution: Wang Mumu